Nature.com The molecule, which targets receptors for the two hormones, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), was developed in DiMarchi's lab. Swiss pharmaceutical company Roche, based in Basel, supported the ...
Reuters In all these cases the scientists found a synergistic effect from combining the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide ). "We are using mother nature's toolkit and we're hoping to find the right combination ... and more »
MedPage Today Both hormones -- glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) -- are secreted from the intestine in response to food intake, and boost insulin production in order to clear glucose from the blood. Most available ...
